Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.46 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3544250 | 0.88 | PLK1 (0.51) | PDGFRBPDGFRAAURKAAURKBCD274 | |
| SCHEMBL3541388 | 0.87 | PLK1 (0.58) | PLK1PLK3PLK2 | |
| SCHEMBL3547445 | 0.80 | RPS6KA3 (0.40) | AURKAAURKBPLK1 | |
| SCHEMBL3540452 | 0.79 | RAD52 (0.59) | PLK1PLK3PLK2 | |
| SCHEMBL3546335 | 0.75 | PLK1 (0.57) | PLK1PLK3PLK2 | |
| SCHEMBL1203524 | 0.74 | PLK1 (0.73) | PLK1PLK3PLK2 | |
| SCHEMBL3538331 | 0.73 | MAPK7 (0.66) | PLK1PLK3PLK2 | |
| SCHEMBL1203674 | 0.73 | PLK1 (0.66) | PLK1PLK3PLK2 | |
| SCHEMBL13756757 | 0.73 | EPHX2 (0.56) | PDGFRBPDGFRAAURKAAURKBKIT | |
| SCHEMBL4528493 | 0.72 | CDK2 (0.68) | AURKAAURKBKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | PDGFRB 2254/4885PDGFRA 3011/4885AURKA 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.